Ongoing Studies

STUDY TYPE (EN)	LOCATION (EN)	COMPANY (EN)	BRANCH (EN)	INVESTIGATOR	PHASE (EN)	STUDY TITLE (EN)	STATUS (EN)	LINK (EN)
CLINICAL TRIAL	IZMIR MPH	ABBVIE TIBBI ILACLAR SAN. VE TIC. LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	ONGOING	https://clinicaltrials.gov/study/NCT04928846
CLINICAL TRIAL	IZMIR MPH	AMGEN ILAC TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	RECITE: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy- Induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer	ONGOING	https://clinicaltrials.gov/study/NCT03362177
CLINICAL TRIAL	IZMIR MPH	AMGEN ILAC TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer	ONGOING	https://clinicaltrials.gov/study/NCT03937154
CLINICAL TRIAL	IZMIR MPH	AMGEN ILAC TIC.LTD.STI.	HEMATOLOGY	PROF DR SECKIN CAGIRGAN	PHASE 2	A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL	ONGOING	https://clinicaltrials.gov/study/NCT04521231
CLINICAL TRIAL	IZMIR MPH	AMGEN ILAC TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy	ONGOING	https://clinicaltrials.gov/study/NCT05740566
CLINICAL TRIAL	IZMIR MPH	AMGEN ILAC TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)	ONGOING	https://clinicaltrials.gov/study/NCT05920356
CLINICAL TRIAL	IZMIR MPH	AMGEN ILAC TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy	ONGOING	https://clinicaltrials.gov/study/NCT06117774
CLINICAL TRIAL	IZMIR MPH	AMGEN ILAC TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy	ONGOING	https://clinicaltrials.gov/study/NCT06691984
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy	ONGOING	https://clinicaltrials.gov/study/NCT05221840
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)	ONGOING	https://clinicaltrials.gov/study/NCT03732820
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer.	ONGOING	https://clinicaltrials.gov/study/NCT03732677
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)	ONGOING	https://clinicaltrials.gov/study/NCT04784715
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)	ONGOING	https://clinicaltrials.gov/study/NCT04884360
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.	ONGOING	https://clinicaltrials.gov/study/NCT04493853
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)	ONGOING	https://clinicaltrials.gov/study/NCT05043090
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)	ONGOING	https://clinicaltrials.gov/study/NCT04550260
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)	ONGOING	https://clinicaltrials.gov/study/NCT05374512
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)	ONGOING	https://clinicaltrials.gov/study/NCT04960709
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study	ONGOING	https://clinicaltrials.gov/study/NCT04964934
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours	ONGOING	https://clinicaltrials.gov/study/NCT05489211
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.	ONGOING	https://clinicaltrials.gov/study/NCT04931654
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)	ONGOING	https://clinicaltrials.gov/study/NCT06120491
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)	ONGOING	https://clinicaltrials.gov/study/NCT04862663
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)	ONGOING	https://clinicaltrials.gov/study/NCT05348577
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence	ONGOING	https://clinicaltrials.gov/study/NCT05774951
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)	ONGOING	https://clinicaltrials.gov/study/NCT06129864
CLINICAL TRIAL	IZMIR MPH	ASTRAZENECA ILAC SAN.VE TIC.LTD.STI.	NEPHROLOGY	PROF DR ERHAN TATAR	PHASE 3	A Double-Blind, Randomised, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension	ONGOING	https://clinicaltrials.gov/study/NCT06344104
CLINICAL TRIAL	IZMIR MPH	BAYER CONSUMER AG	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	Missing	A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH	ONGOING	https://clinicaltrials.gov/study/NCT04597125
CLINICAL TRIAL	IZMIR MPH	BEIGENE	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	ONGOING	https://clinicaltrials.gov/study/NCT05909904
CLINICAL TRIAL	IZMIR MPH	BIONTECH	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer	ONGOING	https://clinicaltrials.gov/study/NCT06449209
CLINICAL TRIAL	IZMIR MPH	BIONTECH	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer	ONGOING	https://clinicaltrials.gov/study/NCT06449222
CLINICAL TRIAL	IZMIR MPH	BIONTECH	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2 / PHASE 3	A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer	ONGOING	https://clinicaltrials.gov/study/NCT06712316
CLINICAL TRIAL	IZMIR MPH	BIONTECH	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer	ONGOING	https://clinicaltrials.gov/study/NCT06712355
CLINICAL TRIAL	IZMIR MPH	BMS CLINICS	HEMATOLOGY	PROF DR SECKIN CAGIRGAN	PHASE 3	A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)	ONGOING	https://clinicaltrials.gov/study/NCT05827016
CLINICAL TRIAL	IZMIR MPH	GILEAD SCİENCES-PRAHS	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer	ONGOING	https://clinicaltrials.gov/study/NCT04527991
CLINICAL TRIAL	IZMIR MPH	GILEAD SCİENCES-PRAHS	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1	ONGOING	https://clinicaltrials.gov/study/NCT05382286
CLINICAL TRIAL	IZMIR MPH	GILEAD SCİENCES-PRAHS	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1	ONGOING	https://clinicaltrials.gov/study/NCT05382299
CLINICAL TRIAL	IZMIR MPH	GILEAD SCİENCES-PRAHS	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer	ONGOING	https://clinicaltrials.gov/study/NCT03547973
CLINICAL TRIAL	IZMIR MPH	ICON ANKARA KLINIK ARASTIRMA DIS. TIC. A.S.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2 / PHASE 3	A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation	ONGOING	https://clinicaltrials.gov/study/NCT04613596
CLINICAL TRIAL	IZMIR MPH	IQVIA TIBBI ISTATISTIK LTD.STI	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1	ONGOING	https://clinicaltrials.gov/study/NCT03523585
CLINICAL TRIAL	IZMIR MPH	IQVIA TIBBI ISTATISTIK LTD.STI	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)	ONGOING	https://clinicaltrials.gov/study/NCT04205812
CLINICAL TRIAL	IZMIR MPH	IQVIA TIBBI ISTATISTIK LTD.STI	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	Missing	A Randomized, Double-Blind, Placebo-Controlled Study of Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Chemotherapy	ONGOING	https://clinicaltrials.gov/study/NCT05874401
CLINICAL TRIAL	IZMIR MPH	IQVIA TIBBI ISTATISTIK LTD.STI	HEMATOLOGY	PROF DR SECKIN CAGIRGAN	PHASE 2	A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease	ONGOING	https://clinicaltrials.gov/study/NCT05643638
CLINICAL TRIAL	IZMIR MPH	IQVIA TIBBI ISTATISTIK LTD.STI	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma	ONGOING	https://clinicaltrials.gov/study/NCT05678673
CLINICAL TRIAL	IZMIR MPH	IQVIA TIBBI ISTATISTIK LTD.STI	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02)	ONGOING	https://clinicaltrials.gov/study/NCT06018337
CLINICAL TRIAL	IZMIR MPH	IQVIA TIBBI ISTATISTIK LTD.STI	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)	ONGOING	https://clinicaltrials.gov/study/NCT06635824
CLINICAL TRIAL	IZMIR MPH	JOHNSON AND JOHNSON SIHHI MALZ. SAN. VE TIC. LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy	ONGOING	https://clinicaltrials.gov/study/NCT02531516
CLINICAL TRIAL	IZMIR MPH	JOHNSON AND JOHNSON SIHHI MALZ. SAN. VE TIC. LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer	ONGOING	https://clinicaltrials.gov/study/NCT03748641
CLINICAL TRIAL	IZMIR MPH	JOHNSON AND JOHNSON SIHHI MALZ. SAN. VE TIC. LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	Missing	Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy	ONGOING	https://clinicaltrials.gov/study/NCT04640623
CLINICAL TRIAL	IZMIR MPH	LILLY ILAC TICARET LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer	ONGOING	https://clinicaltrials.gov/study/NCT04194944
CLINICAL TRIAL	IZMIR MPH	LILLY ILAC TICARET LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer	ONGOING	https://clinicaltrials.gov/study/NCT03155997
CLINICAL TRIAL	IZMIR MPH	LILLY ILAC TICARET LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC	ONGOING	https://clinicaltrials.gov/study/NCT04819100
CLINICAL TRIAL	IZMIR MPH	LILLY ILAC TICARET LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer	ONGOING	https://clinicaltrials.gov/study/NCT05288166
CLINICAL TRIAL	IZMIR MPH	LILLY ILAC TICARET LTD.STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence	ONGOING	https://clinicaltrials.gov/study/NCT05514054
CLINICAL TRIAL	IZMIR MPH	MEDPACE	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2 / PHASE 3	A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)	ONGOING	https://clinicaltrials.gov/study/NCT06225596
CLINICAL TRIAL	IZMIR MPH	HEALTH DATA (MENE RESEARCH)	HEMATOLOGY	PROF DR SECKIN CAGIRGAN	PHASE 3	Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4	ONGOING	https://clinicaltrials.gov/study/NCT05243797
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	ONGOING	https://clinicaltrials.gov/study/NCT05609968
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC	ONGOING	https://clinicaltrials.gov/study/NCT05298423
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)	ONGOING	https://clinicaltrials.gov/study/NCT03036488
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)	ONGOING	https://clinicaltrials.gov/study/NCT03924869
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)	ONGOING	https://clinicaltrials.gov/study/NCT02861573
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)	ONGOING	https://clinicaltrials.gov/study/NCT04634877
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)	ONGOING	https://clinicaltrials.gov/study/NCT05224141
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab	ONGOING	https://clinicaltrials.gov/study/NCT03486873
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer	ONGOING	https://clinicaltrials.gov/study/NCT05722015
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)	ONGOING	https://www.clinicaltrials.gov/study/NCT04895358
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)	ONGOING	https://clinicaltrials.gov/study/NCT05665595
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B	ONGOING	https://clinicaltrials.gov/study/NCT05319730
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)	ONGOING	https://clinicaltrials.gov/study/NCT05933577
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	CARDIOLOGY	PROF DR MEHMET EMRE OZPELIT	PHASE 3	Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk	ONGOING	https://clinicaltrials.gov/study/NCT06008756
CLINICAL TRIAL	IZMIR MPH	MERCK SHARP DOHME ILACLARI LTD. STI.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors	ONGOING	https://clinicaltrials.gov/study/NCT06305754
CLINICAL TRIAL	IZMIR MPH	NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)	ONGOING	https://clinicaltrials.gov/study/NCT05827081
CLINICAL TRIAL	IZMIR MPH	NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S.	NEUROLOGY	PROF DR SERKAN OZAKBAS	PHASE 3	A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension	ONGOING	https://clinicaltrials.gov/study/NCT04926818
CLINICAL TRIAL	IZMIR MPH	NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S.	NEUROLOGY	PROF DR SERKAN OZAKBAS	PHASE 3	An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis	ONGOING	https://clinicaltrials.gov/study/NCT03650114
CLINICAL TRIAL	IZMIR MPH	NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S.	NEPHROLOGY	PROF DR ERHAN TATAR	PHASE 3	A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)	ONGOING	https://clinicaltrials.gov/study/NCT05755386
CLINICAL TRIAL	IZMIR MPH	NOVARTIS SAGLIK GIDA VE TARIM URUNLERI SAN. VE TIC. A.S.	NEUROLOGY	PROF DR SERKAN OZAKBAS	PHASE 3	A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib	ONGOING	https://clinicaltrials.gov/study/NCT05156281
CLINICAL TRIAL	IZMIR MPH	NOVONORDISK	NEUROLOGY	PROF DR OZGE YILMAZ KUSBECI	PHASE 3	A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus)	ONGOING	https://clinicaltrials.gov/study/NCT04777409
CLINICAL TRIAL	IZMIR MPH	NOVONORDISK	NEUROLOGY	PROF DR OZGE YILMAZ KUSBECI	PHASE 3	A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)	ONGOING	https://clinicaltrials.gov/study/NCT04777396
CLINICAL TRIAL	IZMIR MPH	PAREXEL INTERNATIONAL(IRL)LIMITED	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)	ONGOING	https://clinicaltrials.gov/study/NCT05061550
CLINICAL TRIAL	IZMIR MPH	PAREXEL INTERNATIONAL(IRL)LIMITED	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy	ONGOING	https://clinicaltrials.gov/study/NCT06095583
CLINICAL TRIAL	IZMIR MPH	PAREXEL INTERNATIONAL(IRL)LIMITED	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma	ONGOING	https://www.clinicaltrials.gov/study/NCT06054555
CLINICAL TRIAL	IZMIR MPH	PAREXEL INTERNATIONAL(IRL)LIMITED	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study	ONGOING	https://clinicaltrials.gov/study/NCT06492616
CLINICAL TRIAL	IZMIR MPH	PFIZER	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)	ONGOING	https://clinicaltrials.gov/study/NCT05654623
CLINICAL TRIAL	IZMIR MPH	PPD GLOBAL LIMITED	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer	ONGOING	https://clinicaltrials.gov/study/NCT04961996
CLINICAL TRIAL	IZMIR MPH	PPD GLOBAL LIMITED	NEUROLOGY	DOC DR HALIL GULLUOGLU	PHASE 3	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease	ONGOING	https://clinicaltrials.gov/study/NCT06585787
CLINICAL TRIAL	IZMIR MPH	REGENERON	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%	ONGOING	https://clinicaltrials.gov/study/NCT05557591
CLINICAL TRIAL	IZMIR MPH	REGENERON	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2 / PHASE 3	A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%	ONGOING	https://www.clinicaltrials.gov/study/NCT05785767
CLINICAL TRIAL	IZMIR MPH	ROCHE MUSTAHZARLARI SAN. A.S.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Double-blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-risk Muscle-invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy	ONGOING	https://clinicaltrials.gov/study/NCT04660344
CLINICAL TRIAL	IZMIR MPH	ROCHE MUSTAHZARLARI SAN. A.S.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	ONGOING	https://www.clinicaltrials.gov/study/NCT05775289
CLINICAL TRIAL	IZMIR MPH	ROCHE MUSTAHZARLARI SAN. A.S.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2	A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy	ONGOING	https://clinicaltrials.gov/study/NCT05645692
CLINICAL TRIAL	IZMIR MPH	ROCHE MUSTAHZARLARI SAN. A.S.	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma	ONGOING	https://clinicaltrials.gov/study/NCT05904886
CLINICAL TRIAL	IZMIR MPH	SYNEOS HEALTH UK LIMITED	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 2 / PHASE 3	An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1	ONGOING	https://clinicaltrials.gov/study/NCT04534205
CLINICAL TRIAL	IZMIR MPH	SYNEOS HEALTH UK LIMITED	MEDICAL ONCOLOGY	PROF DR CAGATAY ARSLAN	PHASE 3	A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients With Metastatic Non-squamous Non-small Cell Lung Cancer	ONGOING	https://clinicaltrials.gov/study/NCT06643117
STUDY TYPE (EN)	LOCATION (EN)	COMPANY (EN)	BRANCH (EN)	INVESTIGATOR	PHASE (EN)	STUDY TITLE (EN)	STATUS (EN)	LINK (EN)